Ionis Pharmaceuticals (IONS) and Otsuka Pharmaceutical announced that the European Commission has approved Dawnzera in the European Union for the routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older. The approval follows the opinion of the Committee for Medicinal Products for Human Use.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Cathie Wood Doubles Down on High-Potential Biotech Plays
- RBLX, META, GH, IONS: Cathie Wood Loads Up on Roblox, Trims Meta and Biotech Stocks
- Ionis Pharmaceuticals: Underappreciated Bepirovirsen and Multiple Late-Stage Catalysts Support Buy Rating
- Ionis Advances Bepirovirsen After Positive Phase 3 Results
- Ionis partner GSK reports B-Well 1, B-Well 2 studies met primary endpoint